ECSP024346A - Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico - Google Patents

Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico

Info

Publication number
ECSP024346A
ECSP024346A EC2002004346A ECSP024346A ECSP024346A EC SP024346 A ECSP024346 A EC SP024346A EC 2002004346 A EC2002004346 A EC 2002004346A EC SP024346 A ECSP024346 A EC SP024346A EC SP024346 A ECSP024346 A EC SP024346A
Authority
EC
Ecuador
Prior art keywords
act
glon
peptides
methods
pharmacological use
Prior art date
Application number
EC2002004346A
Other languages
English (en)
Inventor
Kevin Clairmont
Clark Pan
James Whelan
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of ECSP024346A publication Critical patent/ECSP024346A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención provee polipéptidos que actúan como agonostas del receptor del GLP-1 y como antagonistass del receptor del glucagón. Dichos polipéptidos son útiles para el tratamiento de individuos con diabetes tipo 2 u otros trastornos metabólicos.
EC2002004346A 2001-10-05 2002-11-20 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico ECSP024346A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32773001P 2001-10-05 2001-10-05

Publications (1)

Publication Number Publication Date
ECSP024346A true ECSP024346A (es) 2003-05-26

Family

ID=23277790

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2002004346A ECSP024346A (es) 2001-10-05 2002-11-20 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
EC2004005094A ECSP045094A (es) 2001-10-05 2004-05-05 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2004005094A ECSP045094A (es) 2001-10-05 2004-05-05 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico

Country Status (27)

Country Link
US (6) US7399745B2 (es)
EP (1) EP1436330A4 (es)
JP (1) JP2005508639A (es)
KR (1) KR20050034580A (es)
CN (1) CN1326876C (es)
AR (1) AR036711A1 (es)
BR (1) BR0213132A (es)
CA (1) CA2462462A1 (es)
CO (1) CO5570710A2 (es)
DO (1) DOP2002000475A (es)
EC (2) ECSP024346A (es)
HN (1) HN2002000282A (es)
HR (1) HRP20040327A2 (es)
HU (1) HUP0401797A2 (es)
IL (1) IL160706A0 (es)
MA (1) MA26228A1 (es)
MX (1) MXPA04002140A (es)
MY (1) MY138267A (es)
NO (1) NO20041792L (es)
NZ (1) NZ532685A (es)
PE (1) PE20030850A1 (es)
PL (1) PL368760A1 (es)
RU (1) RU2334761C2 (es)
SG (2) SG158736A1 (es)
UY (1) UY27469A1 (es)
WO (1) WO2003040309A2 (es)
ZA (1) ZA200403322B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497794A1 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
PT1605897E (pt) 2003-03-19 2012-09-10 Lilly Co Eli Compostos de glp-1 ligado a polietilenoglicol
WO2004111078A2 (en) * 2003-06-18 2004-12-23 Theratechnologies Inc. Compounds that modulate the glucagon response and uses thereof
EP1704165B1 (en) 2003-12-18 2010-03-17 Novo Nordisk A/S Glp-1 compounds
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
BRPI0608516A2 (pt) 2005-03-18 2010-11-16 Novo Nordisk As análogo de glp-1, método para aumentar o tempo de ação em um paciente de um análogo de glp-1, composição farmacêutica, e, uso de um composto
WO2007056362A2 (en) * 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
PE20080840A1 (es) 2006-09-13 2008-08-27 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
EP2124974B1 (en) * 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
AU2008216265B2 (en) * 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2008098693A2 (en) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Convergent synthesis of glp-1
EP2214691B1 (en) * 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト
ES2382579T3 (es) * 2007-12-11 2012-06-11 Cadila Healthcare Limited Peptidomiméticos con actividad antagonista de glucagón y agonista de GLP-1
AU2009210570B2 (en) * 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
CL2009000586A1 (es) * 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
MX337038B (es) * 2008-06-17 2016-02-10 Univ Indiana Res & Tech Corp Co-antagonistas de receptor de glucagon/glp-1.
CN104447980A (zh) * 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
EP2300035B1 (en) * 2008-06-17 2015-08-12 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
EP2373681B1 (en) 2008-12-10 2017-01-18 Glaxosmithkline LLC Pharmaceutical compositions of albiglutide
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
WO2010084173A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
KR101813595B1 (ko) 2010-01-22 2017-12-29 노보 노르디스크 헬스 케어 악티엔게젤샤프트 장기적 생체 내 효능을 갖는 성장 호르몬
US9211342B2 (en) 2010-01-22 2015-12-15 Novo Nordisk Healthcare Ag Stable growth hormone compounds resistant to proteolytic degradation
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
JP5844826B2 (ja) 2011-03-04 2016-01-20 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ リゾホスホリパーゼ阻害剤を含む採血デバイス
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
ME02816B (me) 2011-06-22 2018-01-20 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
HK1198810A1 (en) 2011-11-17 2015-06-12 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
US11045523B2 (en) 2013-04-05 2021-06-29 Novo Nordisk Healthcare Ag Formulation of growth hormone albumin-binder conjugate
MA43289B1 (fr) 2014-01-20 2019-12-31 Hanmi Pharm Ind Co Ltd Insuline à action prolongée et utilisation associée
US10189884B2 (en) 2014-04-28 2019-01-29 The Trustees Of The University Of Pennsylvania Thioamide-modified peptides and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
AU2015294371B2 (en) 2014-07-21 2018-02-01 The Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides and methods for using and producing the same
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
TWI798209B (zh) 2017-03-23 2023-04-11 南韓商韓美藥品股份有限公司 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途
CN111954560A (zh) 2018-02-13 2020-11-17 配体药物公司 胰高血糖素受体拮抗剂
EP3891176B1 (en) 2018-12-04 2024-06-05 Holst, Birgitte Dual agonist glp-1 and neurotensin fusion peptide
US11934931B2 (en) * 2018-12-17 2024-03-19 Shape Security, Inc. Decision tree training using a database system
WO2020254479A1 (en) * 2019-06-18 2020-12-24 Fresenius Kabi Ipsum S.R.L. Process for the manufacture of glucagon
US12406209B1 (en) 2019-06-28 2025-09-02 Shape Security, Inc. Decision tree training using a database system
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CN116635402B (zh) 2021-07-14 2024-03-15 北京质肽生物医药科技有限公司 用于代谢病症的融合多肽
AU2024269420A1 (en) 2023-05-11 2025-11-27 Case Western Reserve University Anxiolytic therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE164852T1 (de) * 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
ES2085004T3 (es) * 1991-01-17 1996-05-16 Zymogenetics Inc Metodos para detectar antagonistas de glucagon.
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
DK0832066T3 (da) * 1995-06-06 2001-11-19 Pfizer Substituerede N-(indol-2-carbonyl)amider og derivater som glycogenphosphorylaseinhibitorer
US5782802A (en) * 1996-03-22 1998-07-21 Vitajet Corporation Multiple use needle-less hypodermic injection device for individual users
US6232310B1 (en) * 1999-03-12 2001-05-15 Novo Nordisk A/S Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Also Published As

Publication number Publication date
KR20050034580A (ko) 2005-04-14
EP1436330A2 (en) 2004-07-14
RU2004114243A (ru) 2005-05-10
RU2334761C2 (ru) 2008-09-27
PE20030850A1 (es) 2003-10-31
AR036711A1 (es) 2004-09-29
UY27469A1 (es) 2003-04-30
US20050153890A1 (en) 2005-07-14
CA2462462A1 (en) 2003-05-15
SG158736A1 (en) 2010-02-26
US20060003934A1 (en) 2006-01-05
MA26228A1 (fr) 2004-07-01
US20050288248A1 (en) 2005-12-29
MY138267A (en) 2009-05-29
US7494978B2 (en) 2009-02-24
US20060003417A1 (en) 2006-01-05
US7488714B2 (en) 2009-02-10
US7488715B2 (en) 2009-02-10
US20060003419A1 (en) 2006-01-05
PL368760A1 (en) 2005-04-04
SG149693A1 (en) 2009-02-27
MXPA04002140A (es) 2005-03-07
CN1564828A (zh) 2005-01-12
HN2002000282A (es) 2002-12-12
CN1326876C (zh) 2007-07-18
JP2005508639A (ja) 2005-04-07
NO20041792L (no) 2004-07-02
HRP20040327A2 (en) 2007-11-30
US7399745B2 (en) 2008-07-15
EP1436330A4 (en) 2006-01-18
DOP2002000475A (es) 2003-06-30
BR0213132A (pt) 2004-10-19
ZA200403322B (en) 2005-05-03
NZ532685A (en) 2006-02-24
WO2003040309A3 (en) 2003-12-18
WO2003040309A2 (en) 2003-05-15
US20060003418A1 (en) 2006-01-05
US7488716B2 (en) 2009-02-10
ECSP045094A (es) 2004-06-28
CO5570710A2 (es) 2005-10-31
HUP0401797A2 (en) 2006-08-28
HK1073117A1 (zh) 2005-09-23
IL160706A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
ECSP024346A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
ES2146552B1 (es) Peptidos inhibidores de tgf/31
EP3878868A4 (en) HUMAN ANTIBODY WITH HIGH AFFINITY TO AND USE OF HUMAN IL-4 RECEPTOR ALPHA
AR064032A1 (es) Usos terapeuticos de polipeptidos heterologos il-17a/f
MX2023014985A (es) Agonista del receptor de glp-1 y composicion y uso del mismo.
CR20110556A (es) Proteinas de fusion rage y metodos de empleo
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
GT200300142A (es) Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
AR103242A1 (es) Compuestos co-agonistas de gip y glp-1
NO20001599D0 (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
EP1883419A4 (en) GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
NO20060259L (no) Melanocortinreseptor 4(MC4) agonist og anvendelser derav
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
CL2021001325A1 (es) Ureas cíclicas.
PE20200150A1 (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
UY26370A1 (es) "imidazo-5-il-aminas bicíclicas, medicamentos que las contienen, su uso para la preparación de medicamentos y procedimiento para su preparación".
PE20221271A1 (es) Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas
ES2125567T3 (es) Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
ES2171196T3 (es) Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño.
ATE393781T1 (de) Somatostatin analoge, deren radiomarkierte derivate und deren verwendung
DK1899334T3 (da) Naphthyridinforbindelser
ES2162493T3 (es) Metodo para el combate de la obesidad.
EP1695968A4 (en) AGONISTS OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR, THEIR PREPARATION AND THEIR USE